PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

被引:86
|
作者
Li, Qian [1 ]
Han, Jingjing [1 ]
Yang, Yonglin [2 ]
Chen, Yu [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing, Peoples R China
[2] Nanjing Med Univ, Affiliated Taizhou Peoples Hosp, Dept Infect Dis, Taizhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
PD-1; inhibitor; PD-L1; hepatocellular carcinoma; immune checkpoint; tumor immune escape; immunotherapy; REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; TREMELIMUMAB PLUS DURVALUMAB; PD-1; BLOCKADE; OPEN-LABEL; CANCER; EXPRESSION; SORAFENIB; THERAPY; MECHANISMS;
D O I
10.3389/fimmu.2022.1070961
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a long time, but there are still many shortcomings. In recent years, with the deepening of research on tumor immune microenvironment, researchers have begun to explore new approaches in immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental changes to the treatment of HCC. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that plays an important role in down-regulating immune system function and promoting tolerance. Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of treatment. Currently, immunotherapy targeting the PD-1/PD-L1 axis has achieved unprecedented success in HCC, but it also faces great challenges, with its low remission rate still to be solved. For most patients with HCC, the PD-1/PD-L1 pathway is not the only rate limiting factor of antitumor immunity, and blocking only the PD-1/PD-L1 axis is not enough to stimulate an effective antitumor immune response; thus, combination therapy may be a better option. In this study, changes in the immune microenvironment of HCC patients were reviewed to clarify the feasibility of anti-PD-1/PD-L1 therapy, and a series of monotherapy and combination therapy clinical trials were summarized to verify the safety and efficacy of this newly developed treatment in patients with advanced HCC. Furthermore, we focused on hyperprogressive disease and drug resistance to gain a better understanding of PD-1/PD-L1 blockade as a promising treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
    Yang, Yao
    Chen, Dongbo
    Zhao, Bigeng
    Ren, Liying
    Huang, Rui
    Feng, Bo
    Chen, Hongsong
    CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
  • [32] PD-1/PD-L1 checkpoint in hematological malignancies
    Annibali, O.
    Crescenzi, A.
    Tomarchio, V.
    Pagano, A.
    Bianchi, A.
    Grifoni, A.
    Avvisati, G.
    LEUKEMIA RESEARCH, 2018, 67 : 45 - 55
  • [33] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
    Sonpavde, Guru
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1073 - 1074
  • [34] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [35] PD-1/PD-L1 and immunotherapy for pancreatic cancer
    Feng, Mengyu
    Xiong, Guangbing
    Cao, Zhe
    Yang, Gang
    Zheng, Suli
    Song, Xujun
    You, Lei
    Zheng, Lianfang
    Zhang, Taiping
    Zhao, Yupei
    CANCER LETTERS, 2017, 407 : 57 - 65
  • [36] Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma
    Chen, Jiaqi
    Zhang, Ding
    Yuan, Ying
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (03) : 579 - 590
  • [37] Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma
    Jiaqi Chen
    Ding Zhang
    Ying Yuan
    Clinical and Experimental Medicine, 2023, 23 : 579 - 590
  • [38] Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents
    Kamal, Monica A.
    Badary, Hedy A.
    Omran, Dalia
    Shousha, Hend I.
    Abdelaziz, Ashraf O.
    El Tayebi, Hend M.
    Mandour, Yasmine M.
    ACS OMEGA, 2023, 8 (37): : 33242 - 33254
  • [39] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Wen, Wen
    Zhang, Yong
    Zhang, Hua
    Chen, Yingshuang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 969 - 978
  • [40] Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
    Zhong, Liting
    Wu, Dehua
    Peng, Weiwei
    Sheng, Hailong
    Xiao, Yazhi
    Zhang, Xuebing
    Wang, Yuli
    FRONTIERS IN ONCOLOGY, 2021, 11